Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept to Report Third Quarter 2017 Financial Results on November 1 and Present at Upcoming Conference
NEW YORK, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its third quarter 2017
View HTML
Toggle Summary Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting® 2017
OCA met the primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeks Results presented in a late-breaking oral session NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization
View HTML
Toggle Summary Intercept Announces Data to be Presented at The Liver Meeting® 2017
Results from the Phase 2 AESOP Trial in Primary Sclerosing Cholangitis to be Presented in Late Breaking Oral Session
View HTML
Toggle Summary Intercept Statement Regarding Ocaliva® (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients
Company to Host Conference Call at 8:30 a.m. ET
View HTML
Toggle Summary Intercept to Present at Upcoming Conferences
NEW YORK, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept to Present at Upcoming Conference
NEW YORK, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis
OCA met the primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeks AESOP represents a successful proof of concept for OCA in a second cholestatic liver disease Conference call scheduled for 8:30 a.m. ET today NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
View HTML
Toggle Summary CONTROL Trial Shows Statin Therapy Reversed LDL Increases to Below Baseline Levels in NASH Patients Treated with OCA
  Low dose atorvastatin rapidly reversed OCA associated LDL changes Conference call scheduled for 8:30 am ET NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
Worldwide net Ocaliva ® (obeticholic acid or OCA) 2Q 2017 sales of $30.4 million AESOP Phase 2 trial in patients with PSC met its primary endpoint CONTROL trial met its objective, confirming statin co-administration with OCA reduces LDL to below baseline levels in patients with NASH Conference call
View HTML
Toggle Summary Intercept to Report Second Quarter 2017 Financial Results on July 31
NEW YORK, July 26, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its second quarter 2017
View HTML